TargetMol

Lucerastat

Product Code:
 
TAR-T32923
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T32923-50mg50mg£870.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T32923-100mg100mg£1,484.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Lucerastat is a very effective and selective α-gal A (α-D-galactosidase) inhibitor for the treatment of lipid storage diseases and Fabry disease.
CAS:
141206-42-0
Formula:
C10H21NO4
Molecular Weight:
219.281
Purity:
0.98
SMILES:
CCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO

References

1. Takai T, Higaki K, Aguilar-Moncayo M, Mena-Barrag?n T, Hirano Y, Yura K, Yu L, Ninomiya H, Garc?a-Moreno MI, Sakakibara Y, Ohno K, Nanba E, Ortiz Mellet C, Garc?a Fern?ndez JM, Suzuki Y. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Mol Ther. 2013 Mar;21(3):526-32. doi: 10.1038/mt.2012.263. Epub 2013 Jan 22. PubMed PMID: 23337983; PubMed Central PMCID: PMC3589148. 2. Kato T, Muraoka M, Hatanaka K. Novel method for chase analysis of oligosaccharide metabolic error caused by xenobiotics. Anal Biochem. 2010 Oct 1;405(1):103-8. doi: 10.1016/j.ab.2010.06.002. Epub 2010 Jun 4. PubMed PMID: 20570645. 3. Kato A, Yamashita Y, Nakagawa S, Koike Y, Adachi I, Hollinshead J, Nash RJ, Ikeda K, Asano N. 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4. doi: 10.1016/j.bmc.2010.04.048. Epub 2010 Apr 21. PubMed PMID: 20457528. 4. Gerrard G, Butters TD, Ganeshaguru K, Mehta AB. Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity. Eur J Pharmacol. 2009 May 1;609(1-3):34-9. doi: 10.1016/j.ejphar.2009.03.018. Epub 2009 Mar 12. PubMed PMID: 19285492.